Febuxostat
- Generic Name
- Febuxostat
- Brand Names
- Adenuric, Uloric, Febuxostat Viatris (previously Febuxostat Mylan), Febuxostat Krka
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16N2O3S
- CAS Number
- 144060-53-7
- Unique Ingredient Identifier
- 101V0R1N2E
- Background
Febuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout who have an inadequate r...
- Indication
Febuxostat is indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. It is not recommended for the treatment of asymptomatic hyperuricemia or secondary hyperuricem...
- Associated Conditions
- Chronic, symptomatic Hyperuricemia
- Associated Therapies
- -
Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Menarini Group
- Target Recruit Count
- 30
- Registration Number
- NCT03605212
- Locations
- 🇭🇺
Debreceni Egyetem Klinikai Központ, Debrecen, Hungary
🇮🇹Ospedale Infantile Regina Margherita, Torino, Italy
🇮🇹Istituto G Gaslini Ospedale Pediatrico IRCCS, Genova, Italy
Uric Acid Effects on Endothelium and Oxydative Stress
- Conditions
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Erasme University Hospital
- Target Recruit Count
- 53
- Registration Number
- NCT03395977
- Locations
- 🇧🇪
Erasme Hospital, Brussels, Belgique, Belgium
Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
- Conditions
- Interventions
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- Mochida Pharmaceutical Company, Ltd.
- Target Recruit Count
- 203
- Registration Number
- NCT03372200
- Locations
- 🇯🇵
Mochida Investigational sites, Tokyo, Japan
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
- Conditions
- Interventions
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT03316131
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 548
- Registration Number
- NCT03200210
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT03131583
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients
- Conditions
- Interventions
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2016-10-25
- Lead Sponsor
- Shanghai 10th People's Hospital
- Target Recruit Count
- 800
- Registration Number
- NCT02944214
- Locations
- 🇨🇳
Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital, Shanghai, Shanghai, China
Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.
- Conditions
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2018-01-02
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 57
- Registration Number
- NCT02866214
Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion
- Conditions
- Interventions
- First Posted Date
- 2016-04-27
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Landspitali University Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT02752633
- Locations
- 🇮🇸
Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
Zurig (Febuxostat) 40mg Efficacy and Safety Trial
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Getz Pharma
- Target Recruit Count
- 50
- Registration Number
- NCT02600780
- Locations
- 🇵🇰
Dow University of Health Sciences, Karachi, Sindh, Pakistan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.